608 results match your criteria: "Lymphangioleiomyomatosis Imaging"
Cureus
November 2024
Internal Medicine, Unidade Local de Saúde de Braga, Braga, PRT.
Lymphangioleiomyomatosis (LAM) is a rare, systemic neoplastic disease that primarily affects women of childbearing age. The disease can arise sporadically or in association with tuberous sclerosis. It is characterized by the proliferation of abnormal smooth muscle-like cells, leading to cystic lung destruction, accumulation of chylous fluid, and development of abdominal tumors.
View Article and Find Full Text PDFBMJ Case Rep
December 2024
University of New South Wales Faculty of Medicine, Sydney, New South Wales, Australia
PLoS One
December 2024
Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Orphanet J Rare Dis
November 2024
Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Lymphangioleiomyomatosis (LAM) is a rare, slowly progressing, low-grade metastatic tumor primarily affecting women. Currently, vascular endothelial growth factor-D (VEGF-D) is the only validated diagnostic biomarker, enabling diagnosis of LAM without the need for lung biopsy in appropriate clinical settings. However, VEGF-D concentrations are normal in about 30% of patients, rendering it insufficient for diagnosing all cases of LAM.
View Article and Find Full Text PDFTuberc Respir Dis (Seoul)
November 2024
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 04763, Republic of Korea.
Chest
November 2024
Critical Care Medicine and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1590, USA. Electronic address:
Clin Imaging
December 2024
University of California, Los Angeles, David Geffen School of Medicine at UCLA, Department of Radiological Sciences, 757 Westwood Plaza, Suite 1621, Los Angeles, CA 90095-7532, USA.
J Magn Reson Imaging
October 2024
Center for Pulmonary Imaging Research, Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Case Rep Womens Health
October 2024
Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Acta Med Port
November 2024
Universidade de Ribeirão Preto (UNAERP) - Campus Guarujá. Guarujá; Diagnósticos da América S.A. (DASA). São Paulo. Brasil.
BMJ Case Rep
September 2024
Division of Pulmonary and Critical Care, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Am J Med Genet A
January 2025
Massachusetts General Hospital, Boston, Massachusetts, USA.
J Thorac Cardiovasc Surg
August 2024
Center for LAM and Rare Lung Diseases at Columbia University, Department of Anesthesiology, Columbia University Irving Medical Center, New York, NY. Electronic address:
Radiology
August 2024
From the Department of Radiology, Qilu Hospital of Shandong University, 107 Wenhua W Rd, Lixia District, Jinan 250012, Shandong, China.
Zhonghua Jie He He Hu Xi Za Zhi
August 2024
Division of Pulmonary and Critical Care Medicine, The first Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, National Centre of Respiratory Medicine, Guangzhou 510120, China.
To describe the prevalence of lymphangioleiomyomatosis-pulmonary hypertension (LAM-PH), to explore the clinical features of patients with LAM-PH, and to evaluate the role of pulmonary artery optical coherence tomography (OCT) in the diagnosis of LAM-PH. Among 234 patients diagnosed with LAM in our center from June 2017 to August 2023, echocardiography was performed in 167 patients, 15 patients with PH indicated by echocardiography were selected as the LAM-PH group. From the remaining 152 patients, 32 patients were randomly selected as the control group.
View Article and Find Full Text PDFDiagnostics (Basel)
July 2024
Laboratory of Imaging Physics, Biochemistry and Biophysics Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
In cystic lung diseases such as lymphangioleiomyomatosis (LAM), a CT-based cyst score that measures the percentage of the lung volume occupied by cysts is a common index of the cyst burden in the lungs. Although the current semi-automatic measurement of the cyst score is well established, it is susceptible to human operator variabilities. We recently developed a fully automatic method incorporating adaptive features in place of manual adjustments.
View Article and Find Full Text PDFJ Med Genet
September 2024
CRCHUM, Montreal, Quebec, Canada
Acad Radiol
December 2024
Center for Pulmonary Imaging Research, Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA; Department of Biomedical Engineering, University of Cincinnati, Cincinnati, Ohio 45221, Cincinnati, Ohio 45229, USA; Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio 45221, USA; Imaging Research Center, Department of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA. Electronic address:
World J Gastroenterol
May 2024
División Patología, Hospital General de Agudos Cosme Argerich, Buenos Aires C1155AHA, Argentina.
In 2013, the World Health Organization defined perivascular epithelioid cell tumor (PEComa) as "a mesenchymal tumor which shows a local association with vessel walls and usually expresses melanocyte and smooth muscle markers." This generic definition seems to better fit the PEComa family, which includes angiomyolipoma, clear cell sugar tumor of the lung, lymphangioleiomyomatosis, and a group of histologically and immunophenotypically similar tumors that include primary extrapulmonary sugar tumor and clear cell myomelanocytic tumor. Clear cell tumors with this immunophenotypic pattern have also had their malignant variants described.
View Article and Find Full Text PDFSaudi J Kidney Dis Transpl
November 2023
Department of Nephrology, The Kidney Centre Post Graduate Training Institute, Karachi, Pakistan.
Renal angiomyolipomas (AMLs) and pulmonary lymphangioleiomyomatosis (LAM) are two major presentations of tuberous sclerosis (TS), an autosomal dominant multisystem disorder. Renal AMLs can lead to life-threatening complications like hemorrhage and cause progressive renal failure requiring dialysis and kidney transplant. mTOR inhibitors showed promising results in TS patients with renal AMLs, LAM, and subependymal giant cell astrocytomas.
View Article and Find Full Text PDFCase Rep Neurol Med
April 2024
Bogomolets National Medical University, Kyiv, Ukraine.
Front Oncol
March 2024
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, United States.
Background: Patients with platinum-resistant recurrent high grade serous ovarian carcinoma have poor outcomes and limited treatment options.
Case Presentation: We present a case of a 48-year-old woman with platinum-resistant high grade serous ovarian carcinoma harboring the pathogenic R611Q variant with concomitant single copy loss of (suggesting biallelic inactivation) identified in targeted tumor sequencing. The patient was treated with the mTOR inhibitor everolimus, with an excellent response by imaging and a marked decrease in CA125; she remained on everolimus for 19 months until she developed progressive disease.